InsidersTradesSigma
Track the REPLIGEN CORP stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, REPLIGEN CORP has recorded 128 public disclosures. Market capitalisation: €8.3bn. The latest transaction was filed on 23 March 2026 (Attribution). Among the most active insiders: Hunt Anthony. Every trade is accessible without an account.
128
Insider Decl.
n/a
Thresholds
€784,575
6 ops.
Buy Volume
€6m
10 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate REPLIGEN CORP Strong Buy (bullish), based on 20 analysts. Average price target: US$178.05.
28Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,743 of 29,063 companies
37.3
score / 100
Value27
Quality48
FCF yld1.0%
Earn yld0.5%
EV/EBITDA54.7x
ROE2.0%
Gross mgn52%
Net mgn6.6%
Debt/EBITDA3.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 March 2026
Declarations128 total
5,284 shares0Common StockSEC:0001193125-26-119047:0
24,134 shares0Common StockSEC:0001193125-26-119036:0
7,751 shares0Common StockSEC:0001193125-26-119034:0
7,751 shares0Common StockSEC:0001193125-26-119031:0
2,506 shares@ US$116.1862.3% of flowCommon StockSEC:0001193125-25-195655:0
4,142 shares0Common StockSEC:0000950170-25-112985:0
1,800 shares@ US$112.12861.5% of flowCommon StockSEC:0000950170-25-107084:0
Canonical exit: 6 Nov 2025 (T+90)
973 shares0Common StockSEC:0000950170-25-075705:0
973 shares0Common StockSEC:0000950170-25-074251:0
973 shares0Common StockSEC:0000950170-25-074761:0
973 shares0Common StockSEC:0000950170-25-074752:0
973 shares0Common StockSEC:0000950170-25-074747:0
973 shares0Common StockSEC:0000950170-25-074224:0
973 shares0Common StockSEC:0000950170-25-074216:0
973 shares0Common StockSEC:0000950170-25-074196:0
2,043 shares@ US$122.662.5% of flowCommon StockSEC:0000950170-25-073387:0
454 shares@ US$128.505.0% of flowCommon StockSEC:0000950170-25-048942:0
381 shares0Common StockSEC:0000950170-25-042471:0
5,000 shares@ US$33.871.7% of flowCommon StockSEC:0000950170-25-042026:0
250 shares@ US$150.69100.0% of flowCommon StockSEC:0000950170-25-041119:0
Canonical exit: 15 Jun 2025 (T+90)
10,142 shares@ US$155.3816.7% of flowCommon StockSEC:0000950170-25-031572:0
4,826 shares0Common StockSEC:0000950170-25-031591:0
6,435 shares0Common StockSEC:0000950170-25-031569:0
14,480 shares0Common StockSEC:0000950170-25-031547:0
6,435 shares0Common StockSEC:0000950170-25-031593:0
25 of 128 declarations
关于 REPLIGEN CORP
Repligen Corp. (NASDAQ: RGEN) 是一家在美国上市的生命科学公司，专注于生物制药生产中使用的生物加工技术。公司总部位于美国马萨诸塞州沃尔瑟姆，作为关键工具、耗材和系统的专业供应商运营，为生物制药的开发和生产提供支持。Repligen 拥有重要的全球业务足迹：虽然其大部分生产基地位于美国，但它在欧洲也设有关键基地，并在亚洲拥有不断增长的业务。其产品通过在美国、欧洲和亚洲的直销团队以及选定的合作伙伴和分销商在全球范围内销售。([repligen.com](https://www.repligen.com/company/about?utm_source=openai)) Repligen 由两位科学家于 1981 年创立，其身份围绕生物加工领域的创新而建立。公司的核心使命是帮助生物制药制造商在提高产量和产品质量的同时，减少生产时间、成本和复杂性。这种战略定位至关重要，因为在生物药物、生物仿制药、生物改良药和新型治疗模式的推动下，更广泛的生物制剂市场持续扩张。因此，Repligen 的商业模式与外包和内部生物制剂生产的结构性增长相关联，而非单一终端市场周期。([repligen.com](https://www.repligen.com/company/about?utm_source=openai)) 从业务线角度来看，Repligen 围绕三个主要特许经营权组织：过滤、分析和蛋白质。在蛋白质领域，公司开发用于纯化工作流程的亲和配体和层析树脂。在分析领域，它销售用于监测制造过程中关键工艺参数和产品质量属性的系统和设备。其过滤特许经营权通过为生物制剂生产中的纯化和浓缩步骤设计的解决方案完善了产品组合。这种组合使 Repligen 能够接触到生物制造过程中高价值、关键任务的阶段，并支持与更广泛的工业供应商相比差异化的竞争优势。([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2026/Repligen-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Financial-Guidance/default.aspx?utm_source=openai)) Repligen 的竞争定位基于专有产品、客户亲密度以及通过内部开发和收购而扩大的产品组合。管理层强调创新、商业扩张和运营规模化是关键优先事项。公司近期披露的信息表明，Repligen 旨在实现持续增长，在分析、过滤和蛋白质领域推出新产品，并投资扩大其国际支持网络。([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2026/Repligen-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Financial-Guidance/default.aspx?utm_source=openai)) 近期里程碑强化了这一战略。2025 年 3 月，Repligen 收购了 908 Devices 的生物工艺分析产品组合，增加了 MAVERICK、MAVEN、REBEL 和 ZipChip 等产品，以加强其分析产品。2025 年，它还推出了 CTech SoloVPE PLUS 系统。2026 年 2 月，公司报告 2025 财年收入为 $738 million，并发布 2026 年指引，预计将进一步增长和利润率扩张。2026 年 4 月，Repligen 在荷兰布雷达开设了欧洲培训与创新中心，彰显其全球客户支持雄心。([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2025/Repligen-Purchases-Bioprocessing-Analytics-Portfolio-from-908-Devices/default.aspx?utm_source=openai))
